News | May 08, 2022
Quality issues force Novartis to suspend production of radioligand therapy medicines
The production suspension impacts commercial and clinical trial supply
The production suspension impacts commercial and clinical trial supply
Infigratinib is not FDA-, Health Canada- or Therapeutics Goods Association-approved for any other indication
In addition, common light chain antibodies generated by RenLite mice can greatly improve the efficiency of downstream assembly of complex drug molecules such as bispecific antibodies and bispecific antibody-drug conjugates (bsADCs)
The DalPhos ligands were developed by Prof. Mark Stradiotto and his research team at the Department of Chemistry, Dalhousie University
New Covid-19 Medriva Rapid Antigen Test kits with very high- sensitivity now available in Australia
MilliporeSigma to become the first company to offer a fully integrated ecosystem for advanced process technologies
Vortioxetine is a novel antidepressant with multimodal activity, which is approved to treat Major Depressive Disorder (MDD) in adults
Ozempic is now approved in the US at 0.5 mg,1.0 mg and 2.0 mg doses for the treatment of type 2 diabetes in adults
The study met its primary endpoint and showed equivalent efficacy and a comparable safety profile
Novel technology combines ACUVUE daily disposable contact lenses with an established antihistamine in FDA- first in its new category
Subscribe To Our Newsletter & Stay Updated
